Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Empiric therapy with beta-blockers

A Hjalmarson1

  • 1Division of Cardiology, Sahlgren's Hospital, University of Göteborg, Sweden.

Pacing and Clinical Electrophysiology : PACE
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.

Clinical pharmacology and therapeutics·2013
Same author

Heart failure and statins--why do we need a clinical trial?

Zeitschrift fur Kardiologie·2005
Same author

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.

Journal of internal medicine·2003
Same author

Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.

Heart (British Cardiac Society)·2003
Same author

Stimulatory activity of anti-peptide antibodies against the second extracellular loop of human M2 muscarinic receptors.

Chinese medical journal·2002
Same author

Detection of interstellar ethylene oxide (c-C2H4O).

The Astrophysical journal·2001
Same journal

Vein of Marshall Alcohol Ablation Facilitated by a 10-French Bidirectional Catheter Supported by Glide Advantage Wire.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Leadless Pacemaker Implantation in High-Risk Patients: Real-World Outcomes From a Multicenter Israeli Registry.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Sex Differences in the Burden of Atrial Fibrillation/Flutter and Associated Heart Failure Stratified by Age at Onset.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Syncope due to Pacing Inhibition During VT Detection in a Conduction System Pacing ICD Programmed in AAI(R) Mode.

Pacing and clinical electrophysiology : PACE·2026
Same journal

When Less Is Too Little: Low Atrioventricular Synchrony by VDD Leadless Pacemaker in a Patient With Glenn Circulation.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Temporal Changes in Left Ventricular Strain in Typical and Atypical Left Bundle Branch Block Patients: A Follow-up Study.

Pacing and clinical electrophysiology : PACE·2026
See all related articles

Beta-blockers are the only drugs proven to reduce sudden cardiac death and mortality after myocardial infarction. These medications, including propranolol, timolol, and metoprolol, should be used for prophylaxis when appropriate.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are the sole drug class demonstrating significant impact on ventricular fibrillation and sudden death in humans.
  • The precise mechanisms behind beta-blockers' prophylactic effects remain unclear, potentially involving anti-ischemic or antiarrhythmic actions.

Purpose of the Study:

  • To recommend the use of beta-blockers with proven efficacy in reducing overall mortality and sudden cardiac death post-myocardial infarction.
  • To highlight the potential benefits of beta-blockers in reducing the risk of new ischemic events, angina, and reinfarction.

Main Methods:

  • Review of existing pharmacological data and clinical evidence regarding beta-blocker efficacy.
  • Comparative analysis of beta-blockers versus other antiarrhythmic agents for specific cardiac conditions.

Related Experiment Videos

Main Results:

  • Beta-blockers, specifically propranolol, timolol, and metoprolol, are indicated for improving prognosis after myocardial infarction in the absence of contraindications.
  • Class I antiarrhythmic agents are effective for symptomatic ventricular arrhythmias but lack evidence for preventing ventricular fibrillation and sudden cardiac death.

Conclusions:

  • Beta-blockers are essential for post-myocardial infarction care to reduce mortality and sudden cardiac death.
  • Further research into the exact mechanisms of beta-blockers' cardioprotective effects is warranted.